13M107: ACR-EULAR Criteria for Clinical Response in ANCA-Associated Vasculitis: A Composite Outcome Measure

Speaker(s)

• 

  Peter Merkel, MD, MPH

  University of Pennsylvania
  Philadelphia, PA, United States

  Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)
• SM

  Sara Monti, MD, PhD

  University of Pavia
  Pavia, Pavia, Italy

  Disclosure(s): CSL Vifor: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, June 2, 2023)
• GT

  Gunnar Tomasson, MD

  University of Iceland
  Reykjavik, Iceland

  Disclosure(s): No financial relationships with ineligible companies to disclose

Virtual Speaker(s)

• 

  Kaitlin Quinn, MD, MHS

  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
  Bethesda, MD, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

The goals of this session are to introduce to the rheumatology community the newly-developed ACR/EULAR Criteria for Clinical Response in ANCA-associated vasculitis. The session will review the rationale for creating such an outcome measure, the background work leading to the development of the measure, and the methodology employed, including how composite measures are created. The final tool will be presented, along with a guide to its use in a clinical trial.

Presentations:

• 7:30 AM - 7:40 AM PT

  Introduction to the Project and Rationale for Developing Criteria for Response for ANCA-Associated Vasculitis
  

  Speaker: Peter A. Merkel, MD, MPH – University of Pennsylvania
• 7:40 AM - 7:50 AM PT

  Results of the Systematic Literature Review and Delphi Exercise
  

  Virtual Speaker: Kaitlin Quinn, MD, MHS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
• 7:50 AM - 8:00 AM PT

  Draft Response Criteria
  

  Speaker: Sara Monti, MD, PhD – University of Pavia
• 8:00 AM - 8:10 AM PT

  Candidate Items for the Response Criteria and Methods for Arriving at Weights
  

  Speaker: Gunnar Tomasson, MD – University of Iceland
• 8:10 AM - 8:20 AM PT

  Validation of Response Criteria and Next Steps/Implementation
  

  Speaker: Peter A. Merkel, MD, MPH – University of Pennsylvania
• 8:10 AM - 9:00 AM PT

  Q&A